BMY
Price
$47.41
Change
+$0.23 (+0.49%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
96.03B
58 days until earnings call
MRK
Price
$85.47
Change
+$1.35 (+1.60%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
210.11B
58 days until earnings call
Interact to see
Advertisement

BMY vs MRK

Header iconBMY vs MRK Comparison
Open Charts BMY vs MRKBanner chart's image
Bristol-Myers Squibb
Price$47.41
Change+$0.23 (+0.49%)
Volume$41.53K
Capitalization96.03B
Merck & Co
Price$85.47
Change+$1.35 (+1.60%)
Volume$118.53K
Capitalization210.11B
BMY vs MRK Comparison Chart in %
Loading...
BMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BMY vs. MRK commentary
Sep 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a Hold and MRK is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 03, 2025
Stock price -- (BMY: $47.18 vs. MRK: $84.12)
Brand notoriety: BMY and MRK are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BMY: 89% vs. MRK: 88%
Market capitalization -- BMY: $96.5B vs. MRK: $213.51B
BMY [@Pharmaceuticals: Major] is valued at $96.5B. MRK’s [@Pharmaceuticals: Major] market capitalization is $213.51B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $659.07B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $89.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BMY’s FA Score shows that 2 FA rating(s) are green whileMRK’s FA Score has 2 green FA rating(s).

  • BMY’s FA Score: 2 green, 3 red.
  • MRK’s FA Score: 2 green, 3 red.
According to our system of comparison, BMY is a better buy in the long-term than MRK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BMY’s TA Score shows that 7 TA indicator(s) are bullish while MRK’s TA Score has 5 bullish TA indicator(s).

  • BMY’s TA Score: 7 bullish, 3 bearish.
  • MRK’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, BMY is a better buy in the short-term than MRK.

Price Growth

BMY (@Pharmaceuticals: Major) experienced а -1.54% price change this week, while MRK (@Pharmaceuticals: Major) price change was -3.72% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.29%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was +10.10%.

Reported Earning Dates

BMY is expected to report earnings on Oct 30, 2025.

MRK is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+0.29% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRK($210B) has a higher market cap than BMY($96B). BMY has higher P/E ratio than MRK: BMY (18.95) vs MRK (12.96). BMY (-13.625) and MRK (-13.856) have similar YTD gains . MRK has higher annual earnings (EBITDA): 25B vs. BMY (15.1B). BMY has more cash in the bank: 13.6B vs. MRK (8.62B). MRK has less debt than BMY: MRK (35.4B) vs BMY (50.9B). MRK has higher revenues than BMY: MRK (63.6B) vs BMY (47.7B).
BMYMRKBMY / MRK
Capitalization96B210B46%
EBITDA15.1B25B60%
Gain YTD-13.625-13.85698%
P/E Ratio18.9512.96146%
Revenue47.7B63.6B75%
Total Cash13.6B8.62B158%
Total Debt50.9B35.4B144%
FUNDAMENTALS RATINGS
BMY vs MRK: Fundamental Ratings
BMY
MRK
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
6
Undervalued
9
Undervalued
PROFIT vs RISK RATING
1..100
10075
SMR RATING
1..100
3327
PRICE GROWTH RATING
1..100
6059
P/E GROWTH RATING
1..100
4391
SEASONALITY SCORE
1..100
192

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BMY's Valuation (6) in the Pharmaceuticals Major industry is in the same range as MRK (9). This means that BMY’s stock grew similarly to MRK’s over the last 12 months.

MRK's Profit vs Risk Rating (75) in the Pharmaceuticals Major industry is in the same range as BMY (100). This means that MRK’s stock grew similarly to BMY’s over the last 12 months.

MRK's SMR Rating (27) in the Pharmaceuticals Major industry is in the same range as BMY (33). This means that MRK’s stock grew similarly to BMY’s over the last 12 months.

MRK's Price Growth Rating (59) in the Pharmaceuticals Major industry is in the same range as BMY (60). This means that MRK’s stock grew similarly to BMY’s over the last 12 months.

BMY's P/E Growth Rating (43) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (91). This means that BMY’s stock grew somewhat faster than MRK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BMYMRK
RSI
ODDS (%)
Bullish Trend 5 days ago
38%
Bearish Trend 5 days ago
49%
Stochastic
ODDS (%)
Bullish Trend 5 days ago
54%
Bullish Trend 5 days ago
61%
Momentum
ODDS (%)
Bearish Trend 5 days ago
52%
Bearish Trend 5 days ago
56%
MACD
ODDS (%)
Bearish Trend 5 days ago
50%
Bearish Trend 5 days ago
53%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
53%
Bearish Trend 5 days ago
50%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
52%
Bullish Trend 5 days ago
47%
Advances
ODDS (%)
Bullish Trend 7 days ago
54%
Bullish Trend 12 days ago
47%
Declines
ODDS (%)
Bearish Trend 9 days ago
54%
Bearish Trend 6 days ago
52%
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
48%
N/A
Aroon
ODDS (%)
Bullish Trend 5 days ago
60%
Bullish Trend 5 days ago
58%
View a ticker or compare two or three
Interact to see
Advertisement
BMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PBE68.450.25
+0.37%
Invesco Biotechnology & Genome ETF
UYG99.900.26
+0.26%
ProShares Ultra Financials
MUSE50.48N/A
N/A
TCW Multisector Credit Income ETF
DYLD22.61-0.03
-0.15%
LeaderShares® Dynamic Yield ETF
VB252.50-1.04
-0.41%
Vanguard Small-Cap ETF

BMY and

Correlation & Price change

A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMY
1D Price
Change %
BMY100%
+0.64%
PFE - BMY
51%
Loosely correlated
+0.65%
MRK - BMY
50%
Loosely correlated
+1.09%
GILD - BMY
47%
Loosely correlated
+0.36%
NVS - BMY
44%
Loosely correlated
+0.06%
GSK - BMY
43%
Loosely correlated
+0.58%
More

MRK and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRK has been loosely correlated with PFE. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRK
1D Price
Change %
MRK100%
+1.09%
PFE - MRK
58%
Loosely correlated
+0.65%
BMY - MRK
50%
Loosely correlated
+0.64%
BIIB - MRK
50%
Loosely correlated
-0.32%
NVS - MRK
48%
Loosely correlated
+0.06%
AZN - MRK
47%
Loosely correlated
-0.11%
More